Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)

BACKGROUND: The endogenous opioid system is a fundamental regulator of mood in humans. Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system modulator, for the adjunctive treatment of major de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuropsychiatr Dis Treat
Main Authors: Zajecka, John M, Stanford, Arielle D, Memisoglu, Asli, Martin, William F, Pathak, Sanjeev
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459143/
https://ncbi.nlm.nih.gov/pubmed/31040679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S199245
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados